Kairos Pharma, Ltd.
KAPA
$0.85
-$0.02-2.00%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -462.06% | -290.71% | 12.34% | -235.58% | -7.20% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | 1,050.00% | 290.00% |
| Total Other Non-Cash Items | 6,975.00% | 280.00% | -127.71% | -- | -- |
| Change in Net Operating Assets | -3,169.23% | 44.48% | -397.56% | -581.30% | -77.97% |
| Cash from Operations | -379.17% | -2,083.33% | -2,831.82% | -2,319.78% | -147.06% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 118.63% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | 3,535.96% | 100.00% | -55.36% | 182.46% |
| Cash from Financing | 49.66% | 3,535.96% | -97.22% | 2,428.57% | 361.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,963.16% | 4,522.64% | -32,316.67% | 2,503.01% | 84.80% |